{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:11:32Z","timestamp":1784563892054,"version":"3.55.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bayerische Staatsministerium f\u00fcr Gesundheit und Pflege","award":["PBN-MGP-2010-0004-DigiOnko"],"award-info":[{"award-number":["PBN-MGP-2010-0004-DigiOnko"]}]},{"name":"Bayerische Staatsministerium f\u00fcr Gesundheit und Pflege","award":["PBN-MGP-2010-0004-DigiOnko"],"award-info":[{"award-number":["PBN-MGP-2010-0004-DigiOnko"]}]},{"name":"Bayerische Staatsministerium f\u00fcr Gesundheit und Pflege","award":["PBN-MGP-2010-0004-DigiOnko"],"award-info":[{"award-number":["PBN-MGP-2010-0004-DigiOnko"]}]},{"DOI":"10.13039\/501100008769","name":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40271-024-00679-6","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T06:01:52Z","timestamp":1709791312000},"page":"349-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Differences in Preferences for Drug Therapy Between Patients with Metastatic Versus Early-Stage Breast Cancer: A Systematic Literature Review"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0158-5402","authenticated-orcid":false,"given":"Lilly Sophia","family":"Brandstetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-5967","authenticated-orcid":false,"given":"Steffi","family":"J\u00edr\u016f-Hillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1771-7249","authenticated-orcid":false,"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-3515","authenticated-orcid":false,"given":"Peter Ulrich","family":"Heuschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-9666","authenticated-orcid":false,"given":"Achim","family":"W\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3545-2552","authenticated-orcid":false,"given":"Jens-Peter","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"issue":"5","key":"679_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014719","volume":"7","author":"M Harrison","year":"2017","unstructured":"Harrison M, Milbers K, Hudson M, Bansback N. Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments. BMJ Open. 2017;7(5): e014719.","journal-title":"BMJ Open"},{"key":"679_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e6572","volume":"345","author":"AG Mulley","year":"2012","unstructured":"Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients\u2019 preferences matter. BMJ. 2012;345: e6572.","journal-title":"BMJ"},{"issue":"4","key":"679_CR3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1001\/jama.300.4.436","volume":"300","author":"M Krahn","year":"2008","unstructured":"Krahn M, Naglie G. The next step in guideline development: incorporating patient preferences. JAMA. 2008;300(4):436\u20138.","journal-title":"JAMA"},{"issue":"9","key":"679_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/00007632-199805010-00023","volume":"23","author":"DK Owens","year":"1998","unstructured":"Owens DK. Spine update. Patient preferences and the development of practice guidelines. Spine. 1998;23(9):1073\u20139.","journal-title":"Spine"},{"issue":"1","key":"679_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1634\/theoncologist.2011-0261","volume":"17","author":"MC Politi","year":"2012","unstructured":"Politi MC, Studts JL, Hayslip JW. Shared decision making in oncology practice: what do oncologists need to know? Oncologist. 2012;17(1):91\u2013100.","journal-title":"Oncologist"},{"issue":"6","key":"679_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3322\/caac.21245","volume":"64","author":"HL Kane","year":"2014","unstructured":"Kane HL, Halpern MT, Squiers LB, Treiman KA, McCormack LA. Implementing and evaluating shared decision making in oncology practice. CA Cancer J Clin. 2014;64(6):377\u201388.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"679_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health."},{"issue":"8","key":"679_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide. Pharmacoeconomics. 2008;26(8):661\u201377.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"679_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1258\/135581907779497602","volume":"12","author":"J Coast","year":"2007","unstructured":"Coast J, Horrocks S. Developing attributes and levels for discrete choice experiments using qualitative methods. J Health Serv Res Policy. 2007;12(1):25\u201330.","journal-title":"J Health Serv Res Policy"},{"issue":"1","key":"679_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","volume":"5","author":"GW Torrance","year":"1986","unstructured":"Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ. 1986;5(1):1\u201330.","journal-title":"J Health Econ"},{"issue":"6","key":"679_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/BF00422221","volume":"2","author":"RM Kaplan","year":"1993","unstructured":"Kaplan RM, Feeny D, Revicki DA. Methods for assessing relative importance in preference based outcome measures. Qual Life Res. 1993;2(6):467\u201375.","journal-title":"Qual Life Res"},{"issue":"2","key":"679_CR12","first-page":"207","volume":"29","author":"A Gafni","year":"1994","unstructured":"Gafni A. The standard gamble method: what is being measured and how it is interpreted. Health Serv Res. 1994;29(2):207\u201324.","journal-title":"Health Serv Res"},{"issue":"3","key":"679_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"679_CR14","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms. In., vol. Version 4.3; 2020."},{"issue":"11","key":"679_CR15","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/cncr.30547","volume":"123","author":"CR Friese","year":"2017","unstructured":"Friese CR, Harrison JM, Janz NK, Jagsi R, Morrow M, Li Y, Hamilton AS, Ward KC, Kurian AW, Katz SJ, et al. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer. 2017;123(11):1925\u201334.","journal-title":"Cancer"},{"issue":"15","key":"679_CR16","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/JCO.2004.09.069","volume":"22","author":"NK Janz","year":"2004","unstructured":"Janz NK, Wren PA, Copeland LA, Lowery JC, Goldfarb SL, Wilkins EG. Patient\u2013physician concordance: preferences, perceptions, and factors influencing the breast cancer surgical decision. J Clin Oncol. 2004;22(15):3091\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"679_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/1534735418762543","volume":"17","author":"MR Andersen","year":"2018","unstructured":"Andersen MR, Sweet E, Hager S, Gaul M, Dowd F, Standish LJ. Use of integrative oncology, involvement in decision-making, and breast cancer survivor health-related quality of life in the first 5 years postdiagnosis. Integr Cancer Ther. 2018;17(3):636\u201345.","journal-title":"Integr Cancer Ther"},{"issue":"8","key":"679_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1200\/JCO.2011.37.7952","volume":"30","author":"R Brown","year":"2012","unstructured":"Brown R, Butow P, Wilson-Genderson M, Bernhard J, Ribi K, Juraskova I. Meeting the decision-making preferences of patients with breast cancer in oncology consultations: impact on decision-related outcomes. J Clin Oncol. 2012;30(8):857\u201362.","journal-title":"J Clin Oncol"},{"issue":"7","key":"679_CR19","first-page":"386","volume":"7","author":"DM daCosta","year":"2014","unstructured":"daCosta DM, Copher R, Basurto E, Faria C, Lorenzo R. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits. 2014;7(7):386\u201396.","journal-title":"Am Health Drug Benefits."},{"issue":"Suppl 7","key":"679_CR20","doi-asserted-by":"publisher","first-page":"vii11","DOI":"10.1093\/annonc\/mds232","volume":"23","author":"F Cardoso","year":"2012","unstructured":"Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annal Oncol. 2012;23(Suppl 7):vii11\u20139.","journal-title":"Annal Oncol"},{"issue":"3","key":"679_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.21037\/cco.2018.05.01","volume":"7","author":"M Hattori","year":"2018","unstructured":"Hattori M, Iwata H. Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable? Chin Clin Oncol. 2018;7(3):23.","journal-title":"Chin Clin Oncol"},{"issue":"6","key":"679_CR22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1634\/theoncologist.8-6-514","volume":"8","author":"CT Chung","year":"2003","unstructured":"Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist. 2003;8(6):514\u201320.","journal-title":"Oncologist"},{"issue":"6","key":"679_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40271-019-00375-w","volume":"12","author":"RL Guerra","year":"2019","unstructured":"Guerra RL, Castaneda L, de Albuquerque RCR, Ferreira CBT, Corr\u00eaa FM, Fernandes RRA, de Almeida LM. Patient preferences for breast cancer treatment interventions: a systematic review of discrete choice experiments. Patient. 2019;12(6):559\u201369.","journal-title":"Patient"},{"issue":"8","key":"679_CR24","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.ctrv.2014.06.007","volume":"40","author":"VC Hamelinck","year":"2014","unstructured":"Hamelinck VC, Bastiaannet E, Pieterse AH, Jannink I, van de Velde CJ, Liefers GJ, Stiggelbout AM. Patients\u2019 preferences for surgical and adjuvant systemic treatment in early breast cancer: a systematic review. Cancer Treat Rev. 2014;40(8):1005\u201318.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"679_CR25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-020-05737-9","volume":"183","author":"CA Minami","year":"2020","unstructured":"Minami CA, King TA, Mittendorf EA. Patient preferences for locoregional therapy in early-stage breast cancer. Breast Cancer Res Treat. 2020;183(2):291\u2013309.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"679_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10549-021-06368-4","volume":"190","author":"JS Sukumar","year":"2021","unstructured":"Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, et al. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2021;190(2):183\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"679_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160.","journal-title":"BMJ"},{"issue":"1","key":"679_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"issue":"4","key":"679_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CGM, Prior T, Marshall DA, Cunningham C, Ijzerman MJ, Bridges JFP. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300\u201315.","journal-title":"Value Health."},{"issue":"12","key":"679_CR30","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495\u20139.","journal-title":"Int J Surg"},{"issue":"16","key":"679_CR31","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2217\/fon-2021-0761","volume":"18","author":"S Amin","year":"2022","unstructured":"Amin S, Tolaney SM, Cambron-Mellott MJ, Beusterien K, Maculaitis MC, Mulvihill E, Shinde R, McLaurin K. Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives. Future Oncol. 2022;18(16):1927\u201341.","journal-title":"Future Oncol"},{"issue":"1","key":"679_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10549-017-4238-0","volume":"164","author":"TJ Ballinger","year":"2017","unstructured":"Ballinger TJ, Kassem N, Shen F, Jiang GL, Smith ML, Railey E, Howell J, White CB, Schneider BP. Discerning the clinical relevance of biomarkers in early stage breast cancer. Breast Cancer Res Treat. 2017;164(1):89\u201397.","journal-title":"Breast Cancer Res Treat"},{"key":"679_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2147\/PPA.S298670","volume":"15","author":"K Beusterien","year":"2021","unstructured":"Beusterien K, Maculaitis MC, Hallissey B, Gaschler MM, Smith ML, Law EH. Patient, oncologist, and payer preferences for adjuvant endocrine therapy and CDK4\/6 inhibitor regimens in early-stage breast cancer: a discrete choice experiment. Patient Prefer Adherence. 2021;15:611\u201323.","journal-title":"Patient Prefer Adherence"},{"key":"679_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.breast.2020.03.001","volume":"51","author":"TC Chou","year":"2020","unstructured":"Chou TC, Chiang SC, Ko Y. Health state utilities for metastatic breast cancer in Taiwan. Breast. 2020;51:57\u201364.","journal-title":"Breast"},{"issue":"11","key":"679_CR35","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/annonc\/mdi370","volume":"16","author":"V Duric","year":"2005","unstructured":"Duric V, Stockler M, Heritier S, Boyle F, Beith J, Sullivan A, Wilcken N, Coates A, Simes R, Duric V, et al. Patients\u2019 preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol. 2005;16(11):1786\u201394.","journal-title":"Ann Oncol"},{"issue":"12","key":"679_CR36","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/sj.bjc.6602874","volume":"93","author":"V Duric","year":"2005","unstructured":"Duric V, Fallowfield L, Saunders C, Houghton J, Coates A, Stockler M, Duric V, Fallowfield L, Saunders C, Houghton J, et al. Patients\u2019 preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile? Br J Cancer. 2005;93(12):1319\u201323.","journal-title":"Br J Cancer"},{"issue":"1","key":"679_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/pon.1045","volume":"16","author":"VM Duric","year":"2007","unstructured":"Duric VM, Butow PN, Sharpe L, Boyle F, Beith J, Wilcken NRC, Heritier S, Coates AS, Simes RJ, Stockler MR. Psychosocial factors and patients\u2019 preferences for adjuvant chemotherapy in early breast cancer. Psychosoc Oncol. 2007;16(1):48\u201359.","journal-title":"Psychosoc Oncol"},{"issue":"2","key":"679_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.pec.2008.02.021","volume":"72","author":"V Duric","year":"2008","unstructured":"Duric V, Butow P, Sharpe L, Heritier S, Boyle F, Beith J, Wilcken N, Coatest A, Simes R, Stockler M, et al. Comparing patients\u2019 and their partners\u2019 preferences for adjuvant chemotherapy in early breast cancer. Patient Educ Couns. 2008;72(2):239\u201345.","journal-title":"Patient Educ Couns"},{"issue":"5","key":"679_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.clbc.2016.04.001","volume":"16","author":"VC Hamelinck","year":"2016","unstructured":"Hamelinck VC, Bastiaannet E, Pieterse AH, de Glas NA, Portielje JE, Merkus JW, den Hoed ID, van de Velde CJ, Liefers GJ, Stiggelbout AM. A prospective comparison of younger and older patients\u2019 preferences for adjuvant chemotherapy and hormonal therapy in early breast cancer. Clin Breast Cancer. 2016;16(5):379\u201388.","journal-title":"Clin Breast Cancer"},{"key":"679_CR40","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2147\/PPA.S52687","volume":"7","author":"M Ishitobi","year":"2013","unstructured":"Ishitobi M, Shibuya K, Komoike Y, Koyama H, Inaji H. Preferences for oral versus intravenous adjuvant chemotherapy among early breast cancer patients. Patient Prefer Adherence. 2013;7:1201\u20136.","journal-title":"Patient Prefer Adherence"},{"issue":"12","key":"679_CR41","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1054\/bjoc.2001.1836","volume":"84","author":"SJ Jansen","year":"2001","unstructured":"Jansen SJ, Kievit J, Nooij MA, de Haes JC, Overpelt IM, van Slooten H, Maartense E, Stiggelbout AM. Patients\u2019 preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer. 2001;84(12):1577\u201385.","journal-title":"Br J Cancer"},{"issue":"1","key":"679_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-013-2727-3","volume":"142","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, Dent SF, Song X, Segal R, Mazzarello S, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Br Cancer Res Treat. 2013;142(1):101\u20137.","journal-title":"Br Cancer Res Treat."},{"key":"679_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2193-1801-3-350","volume":"3","author":"D Lalla","year":"2014","unstructured":"Lalla D, Carlton R, Santos E, Bramley T, D\u2019Souza A. Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis. Springerplus. 2014;3:7.","journal-title":"Springerplus"},{"issue":"4","key":"679_CR44","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1200\/JCO.1998.16.4.1380","volume":"16","author":"C Lindley","year":"1998","unstructured":"Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol. 1998;16(4):1380\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"679_CR45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3747\/co.27.6131","volume":"27","author":"NJ Lipton","year":"2020","unstructured":"Lipton NJ, Jesin J, Warner E, Cao X, Kiss A, Desautels D, Jerzak KJ. Willingness of women with early estrogen receptor-positive breast cancer to take adjuvant CDK4\/6 inhibitors. Curr Oncol. 2020;27(3):127\u201334.","journal-title":"Curr Oncol"},{"key":"679_CR46","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/PPA.S254934","volume":"14","author":"MC Maculaitis","year":"2020","unstructured":"Maculaitis MC, Liu X, Will O, Hanson M, McRoy L, Berk A, Crastnopol M. Oncologist and patient preferences for attributes of CDK4\/6 inhibitor regimens for the treatment of advanced\/metastatic HR positive\/HER2 negative breast cancer: discrete choice experiment and best-worst scaling. Patient Prefer Adherence. 2020;14:2201\u201314.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"679_CR47","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1200\/JCO.1995.13.4.858","volume":"13","author":"RP McQuellon","year":"1995","unstructured":"McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B, Yellen SB. Patient preferences for treatment of metastatic breast-cancer\u2014a study of women with early-stage breast-cancer. J Clin Oncol. 1995;13(4):858\u201368.","journal-title":"J Clin Oncol"},{"issue":"3","key":"679_CR48","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10549-020-05900-2","volume":"184","author":"E Montagna","year":"2020","unstructured":"Montagna E, Pagan E, Bagnardi V, Colleoni M, Cancello G, Munzone E, Dellapasqua S, Bianco N, Campenni G, Iorfida M, et al. Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study. Breast Cancer Res Treat. 2020;184(3):783\u201395.","journal-title":"Breast Cancer Res Treat"},{"key":"679_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.vhri.2020.10.002","volume":"25","author":"A Nazari","year":"2021","unstructured":"Nazari A, Lopez-Valcarcel BG, Najafi S. Preferences of patients with HR+ and HER2- breast cancer regarding hormonal and targeted therapies in the first line of their metastatic stage: a discrete choice experiment. Value Health Region Issues. 2021;25:7\u201314.","journal-title":"Value Health Region Issues."},{"issue":"1","key":"679_CR50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12282-011-0310-5","volume":"20","author":"N Niikura","year":"2013","unstructured":"Niikura N, Kimura M, Iwamoto T, Hayashi N, Shintoku J, Saito Y, Suzuki Y, Tokuda Y. Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment. Breast Cancer. 2013;20(1):67\u201374.","journal-title":"Breast Cancer"},{"issue":"3","key":"679_CR51","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1743-7563.2012.01546.x","volume":"8","author":"DY Oh","year":"2012","unstructured":"Oh DY, Crawford B, Kim SB, Chung HC, McDonald J, Lee SY, Ko SK, Ro J. Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: a multicenter, cross-sectional study. Asia Pac J Clin oncol. 2012;8(3):282\u201391.","journal-title":"Asia Pac J Clin oncol"},{"issue":"5","key":"679_CR52","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12282-019-00965-4","volume":"26","author":"Y Omori","year":"2019","unstructured":"Omori Y, Enatsu S, Cai ZH, Ishiguro H. Patients\u2019 preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan. Breast Cancer. 2019;26(5):652\u201362.","journal-title":"Breast Cancer"},{"issue":"5","key":"679_CR53","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000513139","volume":"16","author":"M Reinisch","year":"2021","unstructured":"Reinisch M, Marschner N, Otto T, Korfel A, Stoffregen C, Wockel A. Patient Preferences: results of a German adaptive choice-based conjoint analysis (Market Research Study sponsored by Eli Lilly and Company) in patients on palliative treatment for advanced breast cancer. Breast Care. 2021;16(5):491\u20139.","journal-title":"Breast Care"},{"issue":"2","key":"679_CR54","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pon.3384","volume":"23","author":"E Senkus","year":"2014","unstructured":"Senkus E, Gomez H, Dirix L, Jerusalem G, Murray E, Van Tienhoven G, Westenberg AH, Bottomley A, Rapion J, Bogaerts J, et al. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3\u201398. Psychosoc Oncol. 2014;23(2):173\u201382.","journal-title":"Psychosoc Oncol"},{"key":"679_CR55","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/oxfordjournals.jncimonographs.a003453","volume":"30","author":"RJ Simes","year":"2001","unstructured":"Simes RJ, Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr. 2001;30:146\u201352.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"679_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10549-014-2909-7","volume":"145","author":"ML Smith","year":"2014","unstructured":"Smith ML, White CB, Railey E, Sledge GW Jr. Examining and predicting drug preferences of patients with metastatic breast cancer: using conjoint analysis to examine attributes of paclitaxel and capecitabine. Breast Cancer Res Treat. 2014;145(1):83\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"679_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00535","author":"S Spaich","year":"2018","unstructured":"Spaich S, Kinder J, Hetjens S, Fuxius S, Gerhardt A, Sutterlin M, Spaich S, Kinder J, Hetjens S, Fuxius S, et al. Patient preferences regarding chemotherapy in metastatic breast cancer-a conjoint analysis for common taxanes. Front Oncol. 2018. https:\/\/doi.org\/10.3389\/fonc.2018.00535.","journal-title":"Front Oncol"},{"issue":"6","key":"679_CR58","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1089\/jayao.2019.0027","volume":"8","author":"A Srikanthan","year":"2019","unstructured":"Srikanthan A, Amir E, Gupta A, Baxter N, Kennedy ED. Assisting with decision-making: how standardized information impacts breast cancer patient decisions regarding fertility trade-offs and chemotherapy. J Adolesc Young Adult oncol. 2019;8(6):660\u20137.","journal-title":"J Adolesc Young Adult oncol"},{"issue":"9","key":"679_CR59","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2217\/fon-2021-0635","volume":"18","author":"E Stamuli","year":"2022","unstructured":"Stamuli E, Corry S, Ross D, Konstantopoulou T, Stamuli E, Corry S, Ross D, Konstantopoulou T. Patient preferences for breast cancer treatments: a discrete choice experiment in France, Ireland, Poland, Spain. Future Oncol. 2022;18(9):1115\u201332.","journal-title":"Future Oncol"},{"issue":"1","key":"679_CR60","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/curroncol28010051","volume":"28","author":"D Stellato","year":"2021","unstructured":"Stellato D, Thabane M, Eichten C, Delea TE. Preferences of Canadian patients and physicians for treatment of HR+\/HER2-advanced breast cancer. Curr Oncol. 2021;28(1):491\u2013508.","journal-title":"Curr Oncol"},{"issue":"8","key":"679_CR61","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(05)70254-0","volume":"6","author":"B Thewes","year":"2005","unstructured":"Thewes B, Meiser B, Duric VM, Stockler MR, Taylor A, Stuart-Harris R, Links M, Wilcken N, McLachlan SA, Phillips KA, et al. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol. 2005;6(8):581\u20138.","journal-title":"Lancet Oncol"},{"issue":"5","key":"679_CR62","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1055\/s-0042-101025","volume":"76","author":"M Thill","year":"2016","unstructured":"Thill M, Pisa G, Isbary G, Thill M, Pisa G, Isbary G. Targets for neoadjuvant therapy\u2014the preferences of patients with early breast cancer. Geburtshilfe Frauenheilkd. 2016;76(5):551\u20136.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"3","key":"679_CR63","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/cncr.33287","volume":"127","author":"CP Williams","year":"2021","unstructured":"Williams CP, Gallagher KD, Deehr K, Aswani MS, Azuero A, Daniel CL, Ford EW, Ingram SA, Balch AJ, Rocque GB. Quantifying treatment preferences and their association with financial toxicity in women with breast cancer. Cancer. 2021;127(3):449\u201357.","journal-title":"Cancer"},{"issue":"1","key":"679_CR64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.7326\/0003-4819-117-1-53","volume":"117","author":"MN Levine","year":"1992","unstructured":"Levine MN, Gafni A, Markham B, MacFarlane D. A bedside decision instrument to elicit a patient\u2019s preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med. 1992;117(1):53\u20138.","journal-title":"Ann Intern Med"},{"issue":"10","key":"679_CR65","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.1997.15.10.3192","volume":"15","author":"VA Palda","year":"1997","unstructured":"Palda VA, LlewellynThomas HA, Mackenzie RG, Pritchard KI, Naylor CD. Breast cancer patients attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. J Clin Oncol. 1997;15(10):3192\u2013200.","journal-title":"J Clin Oncol"},{"issue":"2","key":"679_CR66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00520-008-0505-2","volume":"17","author":"SY Zafar","year":"2009","unstructured":"Zafar SY, Alexander SC, Weinfurt KP, Schulman KA, Abernethy AP. Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer. 2009;17(2):117\u201327.","journal-title":"Support Care Cancer"},{"issue":"S7","key":"679_CR67","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/cncr.23653","volume":"113","author":"AL Back","year":"2008","unstructured":"Back AL, Anderson WG, Bunch L, Marr LA, Wallace JA, Yang HB, Arnold RM. Communication about cancer near the end of life. Cancer. 2008;113(S7):1897\u2013910.","journal-title":"Cancer"},{"key":"679_CR68","unstructured":"Brustkrebs \u2013 Chemotherapie. https:\/\/www.krebsgesellschaft.de\/onko-internetportal\/basis-informationen-krebs\/krebsarten\/brustkrebs\/therapie\/chemotherapie.html"},{"issue":"2","key":"679_CR69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-009-0401-6","volume":"116","author":"M Peate","year":"2009","unstructured":"Peate M, Meiser B, Hickey M, Friedlander M. The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. Breast Cancer Res Treat. 2009;116(2):215\u201323.","journal-title":"Breast Cancer Res Treat"},{"key":"679_CR70","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511753831","volume-title":"Stated choice methods: analysis and applications","author":"JJ Louviere","year":"2000","unstructured":"Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and applications. Cambridge: Cambridge University Press; 2000."},{"issue":"4","key":"679_CR71","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","volume":"3","author":"D Marshall","year":"2010","unstructured":"Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR. Conjoint analysis applications in health\u2014how are studies being designed and reported?: An update on current practice in the published literature between 2005 and 2008. Patient. 2010;3(4):249\u201356.","journal-title":"Patient"},{"issue":"2","key":"679_CR72","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201\u201326.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"679_CR73","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40273-013-0089-7","volume":"31","author":"SM Joy","year":"2013","unstructured":"Joy SM, Little E, Maruthur NM, Purnell TS, Bridges JF. Patient preferences for the treatment of type 2 diabetes: a scoping review. Pharmacoeconomics. 2013;31(10):877\u201392.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"679_CR74","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","volume":"32","author":"MD Clark","year":"2014","unstructured":"Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883\u2013902.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"679_CR75","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.sapharm.2020.02.013","volume":"16","author":"MU Khan","year":"2020","unstructured":"Khan MU, Brien J-A, Aslani P. The use of discrete choice experiments in adherence research: a new solution to an old problem. Res Soc Admin Pharm. 2020;16(10):1487\u201392.","journal-title":"Res Soc Admin Pharm."},{"key":"679_CR76","unstructured":"digiOnko [https:\/\/www.digionko-bayern.de\/]"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-024-00679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-024-00679-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-024-00679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:30:44Z","timestamp":1718897444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-024-00679-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1007\/s40271-024-00679-6","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"11 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This study was supported as a part of the project BRE-BY-MED \u2018Breast Cancer Care in Bavaria for Patients with Metastatic Disease\u2019 (DRKS00026601), which is integrated in the mantle project digiOnko \u2018Integrative Concept for personalised precision medicine in prevention, screening, therapy and recurrence prevention on the example of breast cancer\u2019 [], funded by the Bavarian State Ministry for Health and Care (project grant number PBN-MGP-2010-0004-DigiOnko).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"L.B. and S.J.H. report no conflict of interest. St.S. received speaker honoraria as well as reimbursement of travel costs from AstraZeneca, Bayer, Boehringer-Ingelheim, Sanofi, Servier; received financial support for carrying out clinical studies from AstraZeneca, Bayer, Boehringer-Ingelheim, Novartis, NovoNordisk, Pfizer, Sanofi; received personal payments for Data Safety Monitoring Board or Advisory Board activities from AstraZeneca, Bayer, Boehringer-Ingelheim, NovoNordisk, Sanofi, Servier; unpaid Board Membership in the Writing Group National Guideline Heart Failure Guideline Germany, ESC-HFA Committee of the National Heart Failure Societies, ESC-HFA Patient Website: Heartfailurematters.org, outside the submitted work. P.U.H. reports research grants from the German Ministry of Research and Education, Federal Joint Committee (G-BA) within the Innovationfond, European Union, German Parkinson Society, University Hospital W\u00fcrzburg, German Heart Foundation, German Research Foundation, Bavarian State, German Cancer Aid, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin (within Mondafis; supported by an unrestricted research grant to the Charit\u00e9 from Bayer), University G\u00f6ttingen (within FIND-AF randomized; supported by an unrestricted research grant to the University G\u00f6ttingen from Boehringer-Ingelheim), University Hospital Heidelberg (within RASUNOA-prime; supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo); participation on DSMB in publicly funded studies (by German Research Foundation, German Ministry of Research, Foundations), outside the submitted work. AW reports research grants from the Federal Joint Committee (G-BA) within the Innovationfond, outside the submitted work, consulting fees received from AstraZeneca, Lilly, Novartis, Pfizer, Roche, MSD, Pierre Fabre, Seagen, Exact Sciences, Gilead, Dajichi Sanko; speaker honoraria received from Aurikamed and Onkowissen; support for attending meetings and\/or travel received from Pfizer, Dajichi Sanko; leadership or fiduciary role in AGO, S3-Guideline Breast Cancer, German Society of Breast Cancer (BGGF). J.P.R. reports research grants from the German Ministry of Research and Education, Bavarian State (ministry for science and the arts), Federal Joint Committee (G-BA) within the Innovationfond, German Center for Lung Research; payment for expert testimony from the German Ministry of Health (BMG); payment for EBM Training Lecture by the Landesaerztekammer Hessen, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Data sharing is not applicable to this article as no datasets were generated during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the conception and design of the work. L.B. and S.J.H. contributed to material preparation, data collection and analysis. The first draft of the manuscript was written by L.B. and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}